Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody

mAbs

Volumn 7, Issue 2, 2015, Pages 428-439

  Peng, Li ^a   Oganesyan, Vaheh ^a   Wu, Herren ^a   Dall'Acqua, William F ^a   Damschroder, Melissa M ^a  

^a MEDIMMUNE   (United States)

Author keywords

Anifrolumab; Enzymatic fragmentation; Epitope mapping; IFNAR1; MEDI546; Mutagenesis; Phagepeptide display; Protein docking; Systemic sclerosis

Indexed keywords

ALPHA INTERFERON RECEPTOR; ANIFROLUMAB; COMPLEMENTARY DNA; HUMAN MONOCLONAL ANTIBODY; MESSENGER RNA; ALPHA BETA INTERFERON RECEPTOR; EPITOPE; IFNAR1 PROTEIN, HUMAN; IFNAR2 PROTEIN, HUMAN; INTERFERON; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY;

ARTICLE; AUTOIMMUNE DISEASE; BACTERIOPHAGE; BINDING COMPETITION; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DRUG TARGETING; EPITOPE MAPPING; HUMAN; IMMUNOTHERAPY; LIGAND BINDING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PEPTIDE LIBRARY; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CHEMISTRY; CHO CELL LINE; CRICETULUS; DEFICIENCY; GENETICS; HAMSTER; MALE; METABOLISM; MISSENSE MUTATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CHO CELLS; CRICETINAE; CRICETULUS; EPITOPE MAPPING; EPITOPES; INTERFERONS; MALE; MUTATION, MISSENSE; PEPTIDE LIBRARY; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 84924533345     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1007810     Document Type: Article

References (42)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6(12):975-90; PMID:18049472; http://dx.doi.org/10.1038/nrd2422
2. Garcia-Sastre AC, Biron A. Type 1 interferons and the virus-host relationship: a lesson in détente. Science 2006; 312(5775):879-82; PMID:16690858; http://dx. doi.org/10.1126/science.1125676
3. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197(6):711-23; PMID:12642603; http://dx.doi.org/10.1084/jem.20021553
4. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18(6):676-82; PMID:17011763; http://dx.doi.org/10.1016/j.coi.2006. 09.014
5. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, Chaussabel D, Oommen N, Fischbach M, Shah KR, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010; 62(2):589-98; PMID:20112391; http://dx.doi. org/10.1002/art.27224
6. Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 1990; 60(2):225-34; http://dx.doi.org/10.1016/0092-8674 (90)90738-Z
7. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 1994; 77(3):391-400; PMID:8181059; http://dx.doi.org/10.1016/0092-8674(94)90154-6
8. Cook JR, Cleary CM, Mariano TM, Izotova L, Pestka S. Differential responsiveness of a splice variant of the human type I interferon receptor to interferons. J Biol Chem 1996; 271(23):13448-53; PMID:8662801; http://dx.doi.org/10.1074/jbc.271.23.13448
9. Cutrone EC, Langer JA. Contributions of cloned type I interferon receptor subunits to differential ligand binding. FEBS Lett 1997; 404(2-3):197-202; PMID:9119063; http://dx.doi.org/10.1016/S0014-5793(97)00129-4
10. Cohen B, Novick D, Barak S, Rubinstein M. Ligandinduced association of the type I interferon receptor components. Mol Cell Biol 1995; 15(8):4208-14; PMID:7623815
11. Cleary CM, Donnelly RJ, Soh J, Mariano TM, Pestka S. Knockout and reconstitution of a functional human type I interferon receptor complex. J Biol Chem 1994; 269(29):18747-9; PMID:8034627
12. Constantinescu SN, Croze E, Wang C, Murti A, Basu L, Mullersman JE, Pfeffer LM. Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex. Proc Natl Acad Sci USA 1994; 91 (20):9602-6; http://dx.doi.org/10.1073/ pnas.91.20.9602
13. Eid P, Langer JA, Bailly G, Lejealle R, Guymarho J, Tovey MG. Localization of a receptor nonapeptide with a possible role in the binding of the type I interferons. Eur Cytokine Netw 2000; 11(4):560-73; PMID:11125298
14. Lu J, Chuntharapai A, Beck J, Bass S, Ow A, De Vos AM, Gibbs V, Kim KJ. Structure-function study of the extracellular domain of the human IFN-alpha receptor (hIFNAR1) using blocking monoclonal antibodies: the role of domains 1 and 2. J Immunol 1998; 160 (4):1782-8; PMID:9469437
15. Lamken P, Gavutis M, Peters I, Van der Heyden J, Uzé G, Piehler J. Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1. J Mol Biol 2005; 350(3):476-88; PMID:15946680; http:// dx.doi.org/10.1016/j.jmb.2005.05.008
16. Cajean-Feroldi C, Nosal F, Nardeux PC, Gallet X, Guymarho J, Baychelier F, Sempé P, Tovey MG, Escary JL, Eid P. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity. Biochemistry 2004; 43(39):12498-512; PMID:15449939; http://dx.doi.org/10.1021/bi049111r
17. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011; 146(4):621-32; PMID:21854986; http://dx.doi. org/10.1016/j.cell.2011.06.048
18. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64(Pt 6):700-04; PMID:18560159; http://dx. doi.org/10.1107/S0907444908007877
19. Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, Liang M, White WI, Yoo S, Richman L, et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Clin Pharmacol Ther 2013; 93(6):483-92; PMID:23511714; http://dx.doi.org/10.1038/ clpt.2013.35
20. Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, Simms RW, Peng SL, Yao Y, Elgeioushi N, Chang L, et al. Dose-escalation of human anti-interferon-a receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. See comment in PubMed Commons below Arthritis Res 2014; 16(1):R57
21. Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus-focus on targeting interferon-alpha. Clin Immunol 2012; 143 (3):210-21; PMID:22525889; http://dx.doi.org/ 10.1016/j.clim.2012.03.005
22. Benoit P, Maguire D, Plavec I, Kocher H, Tovey M, Meyer F. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J Immunol 1993; 150(3):707-16; PMID:8423335
23. Goldman LA, Zafari M, Cutrone EC, Dang A, Brickelmeier M, Runkel L, Benjamin CD, Ling LE, Langer JA. Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. J Interferon Cytokine Res 1999; 19(1):15-26; PMID:10048764; http://dx.doi.org/ 10.1089/107999099314379
24. Mazzoni MR, Porchia F, Hamm HE. Proteolytic fragmentation for epitope mapping. Methods Mol Biol 2009; 524:77-86; PMID:19377938; http://dx.doi.org/ 10.1007/978-1-59745-450-6-6
25. Ling LE, Zafari M, Reardon D, Brickelmeier M, Goelz SE, Benjamin CD. Human type I interferon receptor, IFNAR, is a heavily glycosylated 120-130 kD membrane protein. J Interferon Cytokine Res 1995; 15 (1):55-61; PMID:7544230; http://dx.doi.org/10.1089/ jir.1995.15.55
26. Edman P. A method for the determination of the amino acid sequence in peptides. Arch Biochem 1949; 22(3):475.23; PMID:18134557
27. Stoynova L, Solórzano R, Collin ED. Generation of large deletion mutants from plasmid DNA. BioTechniques 2004; 36(3):402-6; PMID:15038154
28. Böttger V, Böttger A. Epitope mapping using phage display peptide libraries. Methods Mol Biol 2009; 524:181-201; PMID:19377945; http://dx.doi.org/ 10.1007/978-1-59745-450-6-13
29. Wang LF. Epitope mapping using homolog-scanning mutagenesis. Methods Mol Biol 2009; 524:289-303; PMID:19377953; http://dx.doi.org/10.1007/978-1-59745-450-6-21
30. Mikawa T, Lkeda M, Shibata T. Epitope mapping by region-specified PCR-mutagenesis. Methods Mol Biol 2009; 524:305-13; PMID:19377954; http://dx.doi. org/10.1007/978-1-59745-450-6-22
31. Teplyakov A, Luo J, Obmolova G, Malia T, Sweet R, Stanfield R, Kodangattil S, Almagro JC, Gilliland J. Antibody modeling assessment II. Structures and models. Proteins 2014; 82:1563-1582; PMID:24633955; http://dx.doi.org/10.1002/prot.24554
32. Orth P, Xiao L, Hernandez L, Reichert P, Sheth P, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F, Karczewski J, Secore S, Ingram R, Mayhood T, Strickland C, Therien A. Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by Xray Crystallography. J Biol Chem 2014; 289:18008-21; PMID:24821719; http://dx.doi.org/10.1074/jbc.M114. 560748
33. Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res 2004; 32:W665-7; PMID:15215472; http:// dx.doi.org/10.1093/nar/gkh381
34. Chen R, Li L, Weng Z. ZDOCK: An Initial-stage Pro-tein-Docking algorithm. Proteins. 2003; 52:80-87; PMID:12784371; http://dx.doi.org/10.1002/prot. 10389
35. Li L, Chen R, Weng Z. RDOCK: refinement of rigidbody protein docking predictions. Proteins 2003; 53:693-707; PMID:14579360; http://dx.doi.org/ 10.1002/prot.10460
36. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: Macromol Crystallogr Pt A 1997; 276:307-26; http://dx.doi.org/10.1016/S0076-6879 (97)76066-X
37. Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D 2010; 66:22-25.
38. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, et al. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 2004; 43 (6):1410-7; PMID:14769016; http://dx.doi.org/ 10.1021/bi035323x
39. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53:240-55; PMID:15299926; http://dx.doi.org/ 10.1107/S0907444996012255
40. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron-density maps and the location of errors in these models. Acta Crystallogr A 1991; 47:110-19; PMID:2025413; http://dx.doi.org/10.1107/S0108-767390010224
41. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102(18):3586-616; PMID:24889800; http://dx. doi.org/10.1021/jp973084f
42. Alegria-Schaffer A, Lodge A, Vattem K. Performing and optimizing Western blots with an emphasis on chemiluminescent detection. Methods Enzymol 2009; 463:573-99; PMID:19892193; http://dx.doi.org/ 10.1016/S0076-6879(09)63033-0